About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 702896, 20 pages
http://dx.doi.org/10.1155/2013/702896
Review Article

Breath Tests in Respiratory and Critical Care Medicine: From Research to Practice in Current Perspectives

110th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, 10th Office of Disease Prevention and Control, Department of Disease Control, Ministry of Public Health, Chiang Mai 50100, Thailand
2Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

Received 19 April 2013; Revised 12 August 2013; Accepted 14 August 2013

Academic Editor: Alejandro Comellas

Copyright © 2013 Attapon Cheepsattayakorn and Ruangrong Cheepsattayakorn. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Tardif, “The determination of acetaldehyde in exhaled breath,” Novartis Foundation Symposium, vol. 285, pp. 125–133, 2007. View at Scopus
  2. C.-Y. Hahn, S.-Y. Huang, H.-C. Ko et al., “Acetaldehyde involvement in positive and negative alcohol expectancies in han Chinese persons with alcoholism,” Archives of General Psychiatry, vol. 63, no. 7, pp. 817–823, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Parameswaran, E. Pizzichini, M. M. Pizzichini, P. Hussack, A. Efthimiadis, and F. E. Hargreave, “Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma,” European Respiratory Journal, vol. 15, no. 3, pp. 486–490, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Nightingale, D. F. Rogers, and P. J. Barnes, “Effect of repeated sputum induction on cell counts in normal volunteers,” Thorax, vol. 53, no. 2, pp. 87–90, 1998. View at Scopus
  5. S. A. Kharitonov and P. J. Barnes, “Clinical aspects of exhaled nitric oxide,” European Respiratory Journal, vol. 16, no. 4, pp. 781–792, 2000. View at Scopus
  6. M. Phillips, J. Herrera, S. Krishnan, M. Zain, J. Greenberg, and R. N. Cataneo, “Variation in volatile organic compounds in the breath of normal humans,” Journal of Chromatography B, vol. 729, no. 1-2, pp. 75–88, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Phillips, “Breath tests in medicine,” Scientific American, vol. 267, no. 1, pp. 74–79, 1992. View at Scopus
  8. W. Miekisch, J. K. Schubert, and G. F. E. Noeldge-Schomburg, “Diagnostic potential of breath analysis—focus on volatile organic compounds,” Clinica Chimica Acta, vol. 347, no. 1-2, pp. 25–39, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Phillips, R. N. Cataneo, R. Condos et al., “Volatile biomarkers of pulmonary tuberculosis in the breath,” Tuberculosis, vol. 87, no. 1, pp. 44–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. E. Habel, E. H. Bursey, B.-S. Rho et al., “Structure of Rv1848 (UreA), the Mycobacterium tuberculosis urease γ subunit,” Acta Crystallographica Section F, vol. 66, no. 7, pp. 781–786, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Maiga, A. Abaza, and W. R. Bishai, “Current tuberculosis diagnostic tools and role of urease breath test,” Indian Journal of Medical Research, vol. 135, no. 5, pp. 731–736, 2012.
  12. L. Zhang, S. B. Mulrooney, A. F. K. Leung et al., “Inhibition of urease by bismuth(III): implications for the mechanism of action of bismuth drugs,” BioMetals, vol. 19, no. 5, pp. 503–511, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Jassal, G. G. Nedeltchev, J.-H. Lee et al., “13[c]-urea breath test as a novel point-of-care biomarker for tuberculosis treatment and diagnosis,” PLoS ONE, vol. 5, no. 8, Article ID e12451, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Phillips, V. Basa-Dalay, J. Blais et al., “Point-of-care breath test for biomarkers of active pulmonary tuberculosis,” Tuberculosis, vol. 92, no. 4, pp. 314–320, 2012. View at Publisher · View at Google Scholar
  15. A. H. Kolk, J. J. van Berkel, M. M. Claassens et al., “Breath analysis as a potential diagnostic tool for tuberculosis,” The International Journal of Tuberculosis and Lung Disease, vol. 16, no. 6, pp. 777–782, 2012. View at Publisher · View at Google Scholar
  16. M. Phillips, V. Basa-Dalay, G. Bothamley et al., “Breath biomarkers of active pulmonary tuberculosis,” Tuberculosis, vol. 90, no. 2, pp. 145–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. T. Chambers, A. Scott-Thomas, and M. Epton, “Developments in novel breath tests for bacterial and fungal pulmonary infection,” Current Opinion in Pulmonary Medicine, vol. 18, no. 3, pp. 228–284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. P. A. Tisdall, G. D. Roberts, and J. P. Anhalt, “Identification of clinical isolates of Mycobacteria with gas-liquid chromatography alone,” Journal of Clinical Microbiology, vol. 10, no. 4, pp. 506–514, 1979. View at Scopus
  19. Y. Zhang, Y. Zhuang, Z. Liu, and J. Ruan, “Identification of twenty-eight species mycobacteria with their cellular fatty acids by capillary gas chromatography,” Acta Microbiologica Sinica, vol. 31, no. 3, pp. 187–197, 1991. View at Scopus
  20. J. J. Parez, M. Fauville-Dufaux, J. L. Dossogne, E. De Hoffmann, and F. Pouthier, “Faster identification of mycobacteria using gas liquid and thin layer chromatography,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 13, no. 9, pp. 717–725, 1994. View at Scopus
  21. R. P. Manginell, A. S. Pimentel, C. D. Mowry et al., “Diagnostic potential of the pulsed discharged helium ionization detector (PDHID) for pathogenic Mycobacterial volatile biomarkers,” Journal of Breath Research, vol. 7, no. 3, Article ID 037107, 2013. View at Publisher · View at Google Scholar
  22. S. Kwiatkowska, U. Szkudlarek, M. Łuczyńska, D. Nowak, and M. Zieba, “Elevated exhalation of hydrogen peroxide and circulating IL-18 in patients with pulmonary tuberculosis,” Respiratory Medicine, vol. 101, no. 3, pp. 574–580, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C.-H. Wang, C.-Y. Liu, H.-C. Lin, C.-T. Yu, K. F. Chung, and H.-P. Kuo, “Increased exhaled nitric oxide in active pulmonary tuberculosis due to inducible NO synthase upregulation in alveolar macrophages,” European Respiratory Journal, vol. 11, no. 4, pp. 809–815, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Jain, D. S. Thaler, M. Maiga et al., “Reporter phage and breath tests: emerging phenotypic assays for diagnosing active tuberculosis, antibiotic resistance, and treatment efficacy,” Journal of Infectious Diseases, vol. 204, no. 4, pp. S1142–S1150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. C. Van Beek, N. V. Nhung, D. N. Sy, P. J. Sterk, E. W. Tiemersma, and F. G. J. Cobelens, “Measurement of exhaled nitric oxide as a potential screening tool for pulmonary tuberculosis,” International Journal of Tuberculosis and Lung Disease, vol. 15, no. 2, pp. 185–191, 2011. View at Scopus
  26. M. Phillips, R. N. Cataneo, A. R. C. Cummin et al., “Detection of lung cancer with volatile markers in the breath,” Chest, vol. 123, no. 6, pp. 2115–2123, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. C.-Y. Liu, C.-H. Wang, T.-C. Chen, H.-C. Lin, C.-T. Yu, and H.-P. Kuo, “Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer,” British Journal of Cancer, vol. 78, no. 4, pp. 534–541, 1998. View at Scopus
  28. M. Phillips, N. Altorki, J. H. M. Austin et al., “Prediction of lung cancer using volatile biomarkers in breath,” Cancer Biomarkers, vol. 3, no. 2, pp. 95–109, 2007. View at Scopus
  29. M. Phillips, N. Altorki, J. H. M. Austin et al., “Detection of lung cancer using weighted digital analysis of breath biomarkers,” Clinica Chimica Acta, vol. 393, no. 2, pp. 76–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Poli, P. Carbognani, M. Corradi et al., “Exhaled volatile organic compounds in patients with non-small cell lung cancer: Cross sectional and nested short-term follow-up study,” Respiratory Research, vol. 6, article 71, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Chen, F. Xu, Y. Wang et al., “A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis,” Cancer, vol. 110, no. 4, pp. 835–844, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Phillips, K. Gleeson, J. M. B. Hughes et al., “Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study,” Lancet, vol. 353, no. 9168, pp. 1930–1933, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Peled, M. Hakim, P. A. Bunn Jr et al., “Non-invasive breath analysis of pulmonary nodules,” Journal of Thoracic Oncology, vol. 7, no. 10, pp. 1528–1533, 2012. View at Publisher · View at Google Scholar
  34. Y. Wang, Y. Hu, D. Wang et al., “The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines,” Cancer Biomarkers, vol. 11, no. 4, pp. 129–137, 2012. View at Publisher · View at Google Scholar
  35. M. M. L. Steeghs, S. M. Cristescu, P. Munnik, P. Zanen, and F. J. M. Harren, “An off-line breath sampling and analysis method suitable for large screening studies,” Physiological Measurement, vol. 28, no. 5, article 005, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. G. E. Carpagnano, A. Spanevello, C. Curci et al., “IL-2, TNF-α, and leptin: local versus systemic concentrations in NSCLC patients,” Oncology Research, vol. 16, no. 8, pp. 375–381, 2007. View at Scopus
  37. G. E. Carpagnano, D. Lacedonia, G. P. Palladino et al., “Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes?” European Journal of Clinical Investigation, vol. 42, no. 5, pp. 478–486, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. G. E. Carpagnano, M. P. Foschino-Barbaro, A. Spanevello et al., “3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 3, pp. 337–341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Ulanowska, E. Trawińska, P. Sawrycki, and B. Buszewski, “Chemotherapy control by breath profile with application of SPME-GC/MS method,” Journal of Separation Science, vol. 35, no. 21, pp. 2908–2913, 2012. View at Publisher · View at Google Scholar
  40. J. Kordiak, J. Szemraj, K. Hamara, P. Bialasiewicz, and D. Nowak, “Complete surgical resection of lung tumor decreases exhalation of mutated KRAS oncogene,” Respiratory Medicine, vol. 106, no. 9, pp. 1293–1300, 2012. View at Publisher · View at Google Scholar
  41. Y. Y. Broza, R. Kremer, U. Tisch, A. Gevorkyan, A. Shiban, and L. A. Best, “A nanomaterial-based breath test for short-term follow-up after lung tumor resection,” Nanomedicine, vol. 9, no. 1, pp. 15–21, 2013.
  42. I. Enache, G. Noel, M. Y. Jeung et al., “Can exhaled NO fraction predict radiotherapy-induced lung toxicity in lung cancer patients,” Radiation Oncology, vol. 7, p. 117, 2012. View at Publisher · View at Google Scholar
  43. W. Carrol, W. Lenney, T. Wang, P. Španěl, A. Alcock, and D. Smith, “Detection of volatile compounds emitted by Pseudomonas aeruginosa using selected ion flow tube mass spectrometry,” Pediatric Pulmonology, vol. 39, no. 5, pp. 452–456, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. W. A. Biernacki, S. A. Kharitonov, and P. J. Barnes, “Exhaled carbon monoxide in patients with lower respiratory tract infection,” Respiratory Medicine, vol. 95, no. 12, pp. 1003–1005, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. C. G. Uasuf, A. Jatakanon, A. James, S. A. Kharitanov, N. M. Wilson, and P. J. Barnes, “Exhaled carbon monoxide in childhood asthma,” Journal of Pediatrics, vol. 135, no. 5, pp. 569–574, 1999. View at Scopus
  46. M. Yamaya, K. Sekizawa, S. Ishizuka, M. Monma, K. Mizuta, and H. Sasaki, “Increased carbon monoxide in exhaled air of subjects with upper respiratory tract infections,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 1, pp. 311–314, 1998. View at Scopus
  47. T. G. Evans, K. Rasmussen, G. Wiebke, and J. B. Hibbs Jr., “Nitric oxide synthesis in patients with advanced HIV infection,” Clinical and Experimental Immunology, vol. 97, no. 1, pp. 83–86, 1994. View at Scopus
  48. M. Haubitz, T. Busch, M. Gerlach et al., “Exhaled nitric oxide in patients with Wegener's granulomatosis,” European Respiratory Journal, vol. 14, no. 1, pp. 113–117, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. S. G. Von Essen, L. A. Scheppers, R. A. Robbins, and K. J. Donham, “Respiratory tract inflammation in swine confinement workers studied using induced sputum and exhaled nitric oxide,” Clinical Toxicology, vol. 36, no. 6, pp. 557–565, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. S. A. Kharitonov, D. Yates, and P. J. Barnes, “Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections,” European Respiratory Journal, vol. 8, no. 2, pp. 295–297, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. C. M. Harrison and C. C. Andersen, “Exhaled breath measures of inflammation: are they useful in neonatal chronic lung disease?” Archives of Disease in Childhood, vol. 90, no. 1, pp. F6–F10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. J. O. N. Lundberg, J. Palm, and K. Alving, “Nitric oxide but not carbon monoxide is continuously released in the human nasal airways,” European Respiratory Journal, vol. 20, no. 1, pp. 100–103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Syhre, J. M. Scotter, and S. T. Chambers, “Investigation into the production of 2-Pentylfuran by Aspergillus fumigatus and other respiratory pathogens in vitro and human breath samples,” Medical Mycology, vol. 46, no. 3, pp. 209–215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Julak, E. Stranska, V. Rosova, and A. Dohnalova, “Chemical analysis of bronchoalveolar lavage in diagnostics of pneumonia,” Clinical Microbiology and Infectious Diseases, vol. 10, pp. 279–283, 2004.
  55. A. Sandrini, A. R. Johnson, P. S. Thomas, and D. H. Yates, “Fractional exhaled nitric oxide concentration is increased in asbestosis and pleural plaques,” Respirology, vol. 11, no. 3, pp. 325–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Lehtonen, P. Oksa, L. Lehtimäki et al., “Increased alveolar nitric oxide concentration and high levels of leukotriene B4 and 8-isoprostane in exhaled breath condensate in patients with asbestosis,” Thorax, vol. 62, no. 7, pp. 602–607, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. S. A. Kharitonov and P. J. Barnes, “Biomarkers of some pulmonary diseases in exhaled breath,” Biomarkers, vol. 7, no. 1, pp. 1–32, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Pelclova, Z. Fenclova, P. Kacer et al., “8-isoprostane and leukotrienes in exhaled breath condensate in Czech subjects with silicosis,” Industrial Health, vol. 45, no. 6, pp. 766–774, 2007. View at Publisher · View at Google Scholar
  59. Z. Ziȩtkowski and A. Bodzenta-łukaszyk, “Exhaled nitric oxide (NO) in patients with respiratory tract diseases,” Polski Merkuriusz Lekarski, vol. 16, no. 92, pp. 115–118, 2004. View at Scopus
  60. L. Lehtimäki, V. Turjanmaa, H. Kankaanranta, S. Saarelainen, P. Hahtola, and E. Moilanen, “Increased bronchial nitric oxide production in patients with asthma measured with a novel method of different exhalation flow rates,” Annals of Medicine, vol. 32, no. 6, pp. 417–423, 2000. View at Scopus
  61. J. Galli, P. Montuschi, G. C. Passali, M. Laruffa, C. Parrilla, and G. Paludetti, “Exhaled nitric oxide measurement in patients affected by nasal polyposis,” Otolaryngol Head Neck Surg, vol. 147, no. 2, pp. 351–356, 2012. View at Publisher · View at Google Scholar
  62. K. Basu, A. Nair, P. A. Williamson, S. Mukhopadhyay, and B. J. Lipworth, “Airway and systemic effects of soluble and suspension formulations of nebulized budesonide in asthmatic children,” Annals of Allergy, Asthma and Immunology, vol. 103, no. 5, pp. 436–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. W. Zetterquist, H. Marteus, M. Johannesson et al., “Exhaled carbon monoxide is not elevated in patients with asthma or cystic fibrosis,” European Respiratory Journal, vol. 20, no. 1, pp. 92–99, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. I. Horváth, L. E. Donnelly, A. Kiss, P. Paredi, S. A. Kharitonov, and P. J. Barnes, “Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress,” Thorax, vol. 53, no. 8, pp. 668–672, 1998. View at Scopus
  65. C. O. Olopade, M. Zakkar, W. I. Swedler, and I. Rubinstein, “Exhaled pentane levels in acute asthma,” Chest, vol. 111, no. 4, pp. 862–865, 1997. View at Scopus
  66. P. Paredi, S. A. Kharitonov, and P. J. Barnes, “Elevation of exhaled ethane concentration in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 4 I, pp. 1450–1454, 2000. View at Scopus
  67. S. Dragonieri, R. Schot, B. J. A. Mertens et al., “An electronic nose in the discrimination of patients with asthma and controls,” The Journal of Allergy and Clinical Immunology, vol. 120, no. 4, pp. 856–862, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. J. F. Hunt, E. Erwin, L. Palmer et al., “Expression and activity of pH-regulatory glutaminase in the human airway epithelium,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 1, pp. 101–107, 2002. View at Scopus
  69. P. Montuschi, S. A. Kharitonov, G. Ciabattoni, and P. J. Barnes, “Exhaled leukotrienes and prostaglandins in COPD,” Thorax, vol. 58, no. 7, pp. 585–588, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Montuschi and P. J. Barnes, “Exhaled leukotrienes and prostaglandins in asthma,” The Journal of Allergy and Clinical Immunology, vol. 109, no. 4, pp. 615–620, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. I. Rahman and F. Kelly, “Biomarkers in breath condensate: a promising new non-invasive technique in free radical research,” Free Radical Research, vol. 37, no. 12, pp. 1253–1266, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. Z. Csoma, S. A. Kharitonov, B. Balint, A. Bush, N. M. Wilson, and P. J. Barnes, “Increased leukotrienes in exhaled breath condensate in childhood asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 10, pp. 1345–1349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Hanazawa, S. A. Kharitonov, and P. J. Barnes, “Increased nitrotyrosine in exhaled breath condensate of patients with asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 4 I, pp. 1273–1276, 2000. View at Scopus
  74. G. Becher, K. Winsel, E. Beck, C. Neubauer, and E. Stresemann, “Breathing condensate as noninvasive measure for mediators from the lower airways,” Pneumologie, vol. 51, no. 2, pp. 456–459, 1997. View at Scopus
  75. T. Hanazawa, S. A. Kharitonov, W. Oldfield, A. B. Kay, and P. J. Barnes, “Nitrotyrosine and cystenyl leukotrienes in breath condensates are increased after withdrawal of steroid treatment in patients with asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 161, p. A919, 2000.
  76. W. A. Biernacki, S. A. Kharitonov, and P. J. Barnes, “Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD,” Thorax, vol. 58, no. 4, pp. 294–298, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Mikami, C. G. Llewellyn-Jones, D. Bayley, S. L. Hill, and R. A. Stockley, “The chemotactic activity of sputum from patients with bronchiectasis,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 3, pp. 723–728, 1998. View at Scopus
  78. Y. Tochino, H. Kanazawa, Y. Ichimaru, K. Asai, S. Kyoh, and K. Hirata, “Nε-(carboxymethyl)lysine, a major advanced glycation end product in exhaled breath condensate as a biomarker of small airway involvement in asthma,” Journal of Asthma, vol. 44, no. 10, pp. 861–866, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. F. W. S. Ko, C. Y. K. Lau, T. F. Leung et al., “Exhaled breath condensate levels of eotaxin and macrophage-derived chemokine in stable adult asthma patients,” Clinical and Experimental Allergy, vol. 36, no. 1, pp. 44–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. P. Montuschi, F. Macagno, P. Parente et al., “Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD,” Thorax, vol. 60, no. 10, pp. 827–833, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. S. V. Culpitt, P. Paredi, S. A. Kharitonov, and P. J. Barnes, “Exhaled carbon monoxide is increased in COPD patients regardless of their smoking habit,” American Journal of Respiratory and Critical Care Medicine, vol. 157, p. A787, 1998.
  82. P. Paredi, S. A. Kharitonov, D. Leak, S. Ward, D. Cramer, and P. J. Barnes, “Exhaled ethane, a marker of lipid peroxidation, is elevated chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 2 I, pp. 369–373, 2000. View at Scopus
  83. W. M. Foster, L. Jiang, P. T. Stetkiewicz, and T. H. Risby, “Breath isoprene: temporal changes in respiratory output after exposure to ozone,” Journal of Applied Physiology, vol. 80, no. 2, pp. 706–710, 1996. View at Scopus
  84. K. N. Jeejeebhoy, “In vivo breath alkane as an index of lipid peroxidation,” Free Radical Biology and Medicine, vol. 10, no. 3-4, pp. 191–193, 1991. View at Scopus
  85. B.-K. Q. Do, H. S. Garewal, N. C. Clements Jr., Y.-M. Peng, and M. P. Habib, “Exhaled ethane and antioxidant vitamin supplements in active smokers,” Chest, vol. 110, no. 1, pp. 159–164, 1996. View at Scopus
  86. C. O. Olopade, J. A. Christon, M. Zakkar et al., “Exhaled pentane and nitric oxide levels in patients with obstructive sleep apnea,” Chest, vol. 111, no. 6, pp. 1500–1504, 1997. View at Scopus
  87. G. E. Carpagnano, A. Spanevello, R. Sabato, A. Depalo, V. Turchiarelli, and M. P. Foschino Barbaro, “Exhaled pH, exhaled nitric oxide, and induced sputum cellularity in obese patients with obstructive sleep apnea syndrome,” Translational Research, vol. 151, no. 1, pp. 45–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Montuschi, D. Currò, E. Ragazzoni, P. Preziosi, and G. Ciabattoni, “Anaphylaxis increases 8-iso-prostaglandin F(2α) release from guinea-pig lung in vitro,” European Journal of Pharmacology, vol. 365, no. 1, pp. 59–64, 1999. View at Publisher · View at Google Scholar · View at Scopus
  89. P. Montuschi, M. Corradi, G. Ciabattoni, J. Nightingale, S. A. Kharitonov, and P. J. Barnes, “Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 1, pp. 216–220, 1999. View at Scopus
  90. L. G. Wood, P. G. Gibson, and M. L. Garg, “Biomarkers of lipid peroxidation, airway inflammation and asthma,” European Respiratory Journal, vol. 21, no. 1, pp. 177–186, 2003. View at Scopus
  91. I. Romieu, A. Barraza-Villarreal, C. Escamilla-Nuñez et al., “Exhaled breath malondialdehyde as a marker of effect of exposure to air pollution in children with asthma,” Journal of Allergy and Clinical Immunology, vol. 121, no. 4, pp. 903–e6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Davidsson, M. Söderström, K. N. Sjöswärd, and B. Schmekel, “Chlorine in breath condensate—a measure of airway affection in pollinosis?” Respiration, vol. 74, no. 2, pp. 184–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. S. A. Kharitonov, L. E. Donnelly, P. Montuschi, M. Corradi, J. V. Collins, and P. J. Barnes, “Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma,” Thorax, vol. 57, no. 10, pp. 889–896, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. P. Montuschi, J. V. Collins, G. Ciabattoni et al., “Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 3 I, pp. 1175–1177, 2000. View at Scopus
  95. G. E. Carpagnano, O. Resta, M. P. Foschino-Barbaro et al., “Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys),” European Journal of Pharmacology, vol. 505, no. 1–3, pp. 169–175, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. G. E. Carpagnano, S. A. Kharitonov, M. P. Foschino-Barbaro, O. Resta, E. Gramiccioni, and P. J. Barnes, “Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation,” Thorax, vol. 59, no. 12, pp. 1016–1019, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. F. W. S. Ko, C. Y. K. Lau, T. F. Leung, G. W. K. Wong, C. W. K. Lam, and D. S. C. Hui, “Exhaled breath condensate levels of 8-isoprostane, growth related oncogene α and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 100, no. 4, pp. 630–638, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Makris, E. Paraskakis, P. Korakas et al., “Exhaled breath condensate 8-isoprostane, clinical parameters, radiological indices and airway inflammation in COPD,” Respiration, vol. 75, no. 2, pp. 138–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Gessner, S. Hammerschmidt, H. Kuhn et al., “Breath condensate nitrite correlates with hyperinflation in chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 101, no. 11, pp. 2271–2278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Malerba and M. MontuschiP., “Non-invasive biomarkers of lung inflammation in smoking subjects,” Current Medicinal Chemistry, vol. 19, no. 2, pp. 187–196, 2012. View at Scopus
  101. M. Corradi, I. Rubinstein, R. Andreoli et al., “Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 10, pp. 1380–1386, 2003. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Corradi, P. Montuschi, L. E. Donnelly, A. Pesci, S. A. Kharitonov, and P. J. Barnes, “Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 4, pp. 854–858, 2001. View at Scopus
  103. C. Gessner, R. Scheibe, M. Wötzel et al., “Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 99, no. 10, pp. 1229–1240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. P. N. R. Dekhuijzen, K. K. H. Aben, I. Dekker et al., “Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 3 I, pp. 813–816, 1996. View at Scopus
  105. C. Schumann, K. Triantafilou, S. Krueger et al., “Detection of erythropoietin in exhaled breath condensate of nonhypoxic subjects using a multiplex bead array,” Mediators of Inflammation, vol. 2006, Article ID 18061, 5 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Mutti, M. Corradi, M. Goldoni, M. V. Vettori, A. Bernard, and P. Apostoli, “Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma,” Chest, vol. 129, no. 5, pp. 1288–1297, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. P. Paredi, P. L. Shah, P. Montuschi et al., “Increased carbon monoxide in exhaled air of patients with cystic fibrosis,” Thorax, vol. 54, no. 10, pp. 917–920, 1999. View at Scopus
  108. S. A. Kharitonov, M. Corradi, L. van Rensen et al., “Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis,” Thorax, vol. 55, no. 3, pp. 205–209, 2000. View at Publisher · View at Google Scholar · View at Scopus
  109. P. Paredi, S. A. Kharitonov, D. Leak et al., “Exhaled ethane is elevated in cystic fibrosis and correlates with carbon monoxide levels and airway obstruction,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 4 I, pp. 1247–1251, 2000. View at Scopus
  110. L. P. Ho, J. A. Innes, and A. P. Greening, “Nitrite levels in breath condensate of patients with cystic fibrosis is elevated in contrast to exhaled nitric oxide,” Thorax, vol. 53, no. 8, pp. 680–684, 1998. View at Scopus
  111. S. J. Linnane, V. M. Keatings, C. M. Costello et al., “Total sputum nitrate plus nitrite is raised during acute pulmonary infection in cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 1, pp. 207–212, 1998. View at Scopus
  112. B. Balint, L. E. Donnelly, T. Hanazawa, S. A. Kharitonov, and P. J. Barnes, “Increased nitric oxide metabolites in exhaled breath condensate after exposure to tobacco smoke,” Thorax, vol. 56, no. 6, pp. 456–461, 2001. View at Publisher · View at Google Scholar · View at Scopus
  113. K. L. Jones, A. H. Hegab, B. C. Hillman et al., “Elevation of nitrotyrosine and nitrate concentrations in cystic fibrosis sputum,” Pediatric Pulmonology, vol. 30, pp. 79–85, 2000.
  114. M. Corradi, P. Montuschi, L. E. Donnelly, M. E. Hodson, S. A. Kharitonov, and P. J. Barnes, “Nitrosothiols and nitrite in exhaled breath condensate of patients with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 159, p. A682, 1999.
  115. H. Grasemann, B. Gaston, K. Fang, K. Paul, and F. Ratjen, “Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function,” The Journal of Pediatrics, vol. 135, no. 6, pp. 770–772, 1999. View at Scopus
  116. S. Celio, H. Troxler, S. S. Durka et al., “Free 3-nitrotyrosine in exhaled breath condensates of children fails as a marker for oxidative stress in stable cystic fibrosis and asthma,” Nitric Oxide, vol. 15, no. 3, pp. 226–232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Barker, M. Hengst, J. Schmid et al., “Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis,” European Respiratory Journal, vol. 27, no. 5, pp. 929–936, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. C. M. H. H. T. Robroeks, Q. Jöbsis, J. G. M. C. Damoiseaux et al., “Cytokines in exhaled breath condensate of children with asthma and cystic fibrosis,” Annals of Allergy, Asthma and Immunology, vol. 96, no. 2, pp. 349–355, 2006. View at Scopus
  119. A. Bodini, C. D'Orazio, D. G. Peroni et al., “IL-8 and pH values in exhaled condensate after antibiotics in cystic fibrosis children,” International Journal of Immunopathology and Pharmacology, vol. 20, no. 3, pp. 467–472, 2007. View at Scopus
  120. C. Coop, L. L. Hagan, and J. P. Dice, “Exhaled breath condensate pH in the evaluation of asthma,” Allergy and Asthma Proceedings, vol. 29, no. 1, pp. 51–54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. R. Accordino, A. Visentin, A. Bordin et al., “Long-term repeatability of exhaled breath condensate pH in asthma,” Respiratory Medicine, vol. 102, no. 3, pp. 377–381, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. Y. Bujanover, Y. Peled, and H. Blau, “Methane production in patients with cystic fibrosis,” Journal of Pediatric Gastroenterology and Nutrition, vol. 6, no. 3, pp. 377–380, 1987. View at Scopus
  123. J. L. Fridge, C. Conrad, L. Gerson, R. O. Castillo, and K. Cox, “Risk factors for small bowel bacterial overgrowth in cystic fibrosis,” Journal of Pediatric Gastroenterology and Nutrition, vol. 44, no. 2, pp. 212–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. R. Skiepko, Z. Zietkowski, M. M. Tomasiak, and A. Bodzenta-Lukaszyk, “Exhaled breath condensate in the assessment of airway inflammation,” Przegląd Lekarski, vol. 63, no. 12, pp. 1321–1325, 2006. View at Scopus
  125. J. Hunt, “Exhaled breath condensate: an evolving tool for noninvasive evaluation of lung disease,” The Journal of Allergy and Clinical Immunology, vol. 110, no. 1, pp. 28–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  126. S. A. Kharitonov and P. J. Barnes, “Exhaled markers of inflammation,” Current Opinion in Allergy and Clinical Immunology, vol. 1, no. 3, pp. 217–224, 2001. View at Scopus
  127. B. Buszewski, M. Kesy, T. Ligor, and A. Amann, “Human exhaled air analytics: biomarkers of diseases,” Biomedical Chromatography, vol. 21, no. 6, pp. 553–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Kanoh, H. Kobayashi, and K. Motoyoshi, “Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases,” Chest, vol. 128, no. 4, pp. 2387–2392, 2005. View at Publisher · View at Google Scholar · View at Scopus
  129. A. Van Muylem, C. Knoop, and M. Estenne, “Early detection of chronic pulmonary allograft dysfunction by exhaled biomarkers,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 7, pp. 731–736, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. K. Czebe, T. Kullmann, E. Csiszer, E. Barat, I. Horvath, and B. Antus, “Variability of exhaled breath condensate pH in lung transplant recipients,” Respiration, vol. 75, no. 3, pp. 322–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  131. M. A. E. Lärstad, K. Torén, B. Bake, and A.-C. Olin, “Determination of ethane, pentane and isoprene in exhaled air—effects of breath-holding, flow rate and purified air,” Acta Physiologica, vol. 189, no. 1, pp. 87–98, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. M. Lärstad, A.-S. Söderling, K. Caidahl, and A.-C. Olin, “Selective quantification of free 3-nitrotyrosine in exhaled breath condensate in asthma using gas chromatography/tandem mass spectrometry,” Nitric Oxide, vol. 13, no. 2, pp. 134–144, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. A. Emelyanov, G. Fedoseev, A. Abulimity et al., “Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients,” Chest, vol. 120, no. 4, pp. 1136–1139, 2001. View at Publisher · View at Google Scholar · View at Scopus
  134. I. Horvath, S. Loukides, T. Wodehouse, S. A. Kharitonov, P. J. Cole, and P. J. Barnes, “Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress,” Thorax, vol. 53, no. 10, pp. 867–870, 1998. View at Scopus
  135. K. W. Tsang, R. Leung, P. C.-W. Fung et al., “Exhaled and sputum nitric oxide in bronchiectasis: correlation with clinical parameters,” Chest, vol. 121, no. 1, pp. 88–94, 2002. View at Publisher · View at Google Scholar · View at Scopus
  136. J. D. Antuni, S. Ward, D. S. Cramer, S. A. Kharitonov, and P. J. Barnes, “Uptake and elimination of exhaled carbon monoxide in patients with interstitial lung disease is related to the degree ofimpairment of carbon monoxide diffusion capacity,” American Journal of Respiratory and Critical Care Medicine, vol. 159, p. A86, 1999.
  137. S. A. Kharitonov, J. B. Cailes, C. M. Black, R. M. Du Bois, and P. J. Barnes, “Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension,” Thorax, vol. 52, no. 12, pp. 1051–1055, 1997. View at Scopus
  138. G. Rolla, P. Colagrande, E. Scappaticci et al., “Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension,” Journal of Rheumatology, vol. 27, no. 7, pp. 1693–1698, 2000. View at Scopus
  139. A. Giaid and D. Saleh, “Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension,” The New England Journal of Medicine, vol. 333, no. 4, pp. 214–221, 1995. View at Publisher · View at Google Scholar · View at Scopus
  140. S. M. Black, J. R. Fineman, R. H. Steinhorn, J. Bristow, and S. J. Soifer, “Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension,” American Journal of Physiology, vol. 275, no. 5, pp. H1643–H1651, 1998. View at Scopus
  141. R. C. Tyler, M. Muramatsu, S. H. Abman et al., “Variable expression of endothelial no synthase in three forms of rat pulmonary hypertension,” American Journal of Physiology, vol. 276, no. 2, pp. L297–L303, 1999. View at Scopus
  142. A. D. Everett, T. D. Le Cras, C. Xue, and R. A. Johns, “eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow,” American Journal of Physiology, vol. 274, no. 6, pp. L1058–L1065, 1998. View at Scopus
  143. D. Saleh, P. J. Barnes, and A. Giaid, “Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 5, pp. 1763–1769, 1997. View at Scopus
  144. P. Paredi, S. A. Kharitonov, S. Loukides, P. Pantelidis, R. M. Du Bois, and P. J. Barnes, “Exhaled nitric oxide is increased in active fibrosing alveolitis,” Chest, vol. 115, no. 5, pp. 1352–1356, 1999. View at Publisher · View at Google Scholar · View at Scopus
  145. D. M. O'donnell, J. Moynihan, G. A. Finlay et al., “Exhaled nitric oxide and bronchoalveolar lavage nitrite/nitrate in active pulmonary sarcoidosis,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 6, pp. 1892–1896, 1997. View at Scopus
  146. Y. P. Moodley, R. Chetty, and U. G. Lalloo, “Nitric oxide levels in exhaled air and inducible nitric oxide synthase immunolocalization in pulmonary sarcoidosis,” European Respiratory Journal, vol. 14, no. 4, pp. 822–827, 1999. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Rozy, J. Czerniawska, A. Stȩpniewska et al., “Inflammatory markers in the exhaled breath condensate of patients with pulmonary sacroidosis,” Journal of Physiology and Pharmacology, vol. 57, no. 4, pp. 335–340, 2006. View at Scopus
  148. W. J. Piotrowski, A. Antczak, J. Marczak, A. Nawrocka, Z. Kurmanowska, and P. Górski, “Eicosanoids in exhaled breath condensate and BAL fluid of patients with sarcoidosis,” Chest, vol. 132, no. 2, pp. 589–596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  149. P. J. Montuschi, “LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation,” Journal of Chromatography B, vol. 877, no. 13, pp. 1272–1280, 2009. View at Publisher · View at Google Scholar
  150. P. Montuschi, D. Paris, D. Melck et al., “NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis,” Thorax, vol. 67, no. 3, pp. 222–228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  151. Z. L. Borrill, K. Roy, and D. Singh, “Exhaled breath condensate biomarkers in COPD,” European Respiratory Journal, vol. 32, no. 2, pp. 472–486, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. S. Carraro, S. Rezzi, F. Reniero et al., “Metabolomics applied to exhaled breath condensate in childhood asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 10, pp. 986–990, 2007. View at Publisher · View at Google Scholar · View at Scopus
  153. J. Scholpp, J. K. Schubert, W. Miekisch, and K. Geiger, “Breath markers and soluble lipid peroxidation markers in critically III patients,” Clinical Chemistry and Laboratory Medicine, vol. 40, no. 6, pp. 587–594, 2002. View at Publisher · View at Google Scholar · View at Scopus
  154. C. Turner, P. Španěl, and D. Smith, “A longitudinal study of ammonia, acetone and propanol in the exhaled breath of 30 subjects using selected ion flow tube mass spectrometry, SIFT-MS,” Physiological Measurement, vol. 27, no. 4, pp. 321–337, 2006. View at Publisher · View at Google Scholar · View at Scopus
  155. S. T. Senthilmohan, D. B. Milligan, M. J. McEwan, C. G. Freeman, and P. F. Wilson, “Quantitative analysis of trace gases of breath during exercise using the new SIFT-MS technique,” Redox Report, vol. 5, no. 2-3, pp. 151–153, 2000. View at Scopus
  156. J. K. Schubert, W. P. E. Müller, A. Benzing, and K. Geiger, “Application of a new method for analysis of exhaled gas in critically ill patients,” Intensive Care Medicine, vol. 24, no. 5, pp. 415–421, 1998. View at Publisher · View at Google Scholar · View at Scopus
  157. Y. Ishibe, R. Liu, J. Hirosawa, K. Kawamura, K. Yamasaki, and N. Saito, “Exhaled nitric oxide level decreases after cardiopulmonary bypass in adult patients,” Critical Care Medicine, vol. 28, no. 12, pp. 3823–3827, 2000. View at Scopus
  158. E. D. Moloney, S. E. Mumby, R. Gajdocsi et al., “Exhaled breath condensate detects markers of pulmonary inflammation after cardiothoracic surgery,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 1, pp. 64–69, 2004. View at Scopus
  159. S. A. Kharitonov and P. J. Barnes, “Exhaled markers of pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 7, pp. 1693–1722, 2001. View at Scopus
  160. K. W. Garey, M. M. Neuhauser, A. L. Rafice, R. A. Robbins, L. H. Danziger, and I. Rubinstein, “Protein, nitrite/nitrate, and cytokine concentration in exhaled breath condensate of young smokers,” American Journal of Respiratory and Critical Care Medicine, vol. 161, p. A175, 2000.
  161. T. Tsuburai, H. Mita, N. Tsurikisawa et al., “The relationship between cysteinyl leukotriene in exhaled breath condensate and the severity of asthma in adult asthmatics in Japan,” Japanese Journal of Allergology, vol. 57, no. 2, pp. 121–129, 2008. View at Scopus
  162. A. V. Emel'ianov, M. A. Petrova, O. V. Lavrova, L. I. Guleva, A. F. Dolgodvorov, and G. B. Fedoseev, “Disorders in mineral metabolism at different stages of the development of bronchial asthma,” Terapevticheskii Arkhiv, vol. 67, no. 8, pp. 45–47, 1995. View at Scopus
  163. B. G. Stone, T. J. Besse, W. C. Duane, C. D. Evans, and E. G. DeMaster, “Effect of regulating cholesterol biosynthesis on breath isoprene excretion in men,” Lipids, vol. 28, no. 8, pp. 705–708, 1993. View at Scopus
  164. C. M. F. Kneepkens, C. Ferreira, G. Lepage, and C. C. Roy, “The hydrocarbon breath test in the study of lipid peroxidation: principles and practice,” Clinical and Investigative Medicine, vol. 15, no. 2, pp. 163–186, 1992. View at Scopus
  165. Breath test for the detection of various diseases-Patent 6540691. Summary of the invention, p. 15, http://www.freepatentsonline.com/6540691.html, 2008.
  166. S. A. Kharitonov, “Exhaled markers of inflammatory lung diseases: Ready for routine monitoring?” Swiss Medical Weekly, vol. 134, no. 13-14, pp. 175–192, 2004. View at Scopus
  167. L. M. Van Den Toorn, J.-B. Prins, S. E. Overbeek, H. C. Hoogsteden, and J. C. De Jongste, “Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 3 I, pp. 953–957, 2000. View at Scopus
  168. S. A. Kharitonov, D. H. Yates, and P. J. Barnes, “Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients,” American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 1, pp. 454–457, 1996. View at Scopus
  169. P. F. G. Gannon, J. Belcher, C. F. A. Pantin, and P. S. Burge, “The effect of patient technique and training on the accuracy of self- recorded peak expiratory flow,” European Respiratory Journal, vol. 14, no. 1, pp. 28–31, 1999. View at Publisher · View at Google Scholar · View at Scopus
  170. S. A. Kharitonov, F. Gonio, C. Kelly, S. Meah, and P. J. Barnes, “Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children,” European Respiratory Journal, vol. 21, no. 3, pp. 433–438, 2003. View at Scopus
  171. P. E. Silkoff, “Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 6, pp. 2104–2117, 1999. View at Scopus
  172. S. A. Kharitonov and P. J. Barnes, “Does exhaled nitric oxide reflect asthma control? Yes, it does!,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 5, pp. 727–728, 2001. View at Scopus
  173. A.-C. Olin, B. Bake, and K. Torén, “Fraction of exhaled nitric oxide at 50 mL/s: reference values for adult lifelong never-smokers,” Chest, vol. 131, no. 6, pp. 1852–1856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  174. M. Olivieri, M. Malerba, G. Talamini, and M. Corradi, “Reference values for exhaled nitric oxide in the general population,” Chest, vol. 133, no. 3, pp. 831–832, 2008. View at Publisher · View at Google Scholar · View at Scopus
  175. American Thoracic Society; European Respiratory Society, “ATS/ERS recommendations for standardized procedures for online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 8, pp. 912–930, 2005. View at Publisher · View at Google Scholar
  176. M. Olivieri, G. Talamini, M. Corradi et al., “Reference values for exhaled nitric oxide (reveno) study,” Respiratory Research, vol. 7, article 94, 2006. View at Publisher · View at Google Scholar · View at Scopus
  177. G. Rolla, G. Guida, E. Heffler et al., “Diagnostic classification of persistent rhinitis and its relationship to exhaled nitric oxide and asthma: a clinical study of a consecutive series of patients,” Chest, vol. 131, no. 5, pp. 1345–1352, 2007. View at Publisher · View at Google Scholar · View at Scopus
  178. S. Vahlkvist, M. Sinding, K. Skamstrup, and H. Bisgaard, “Daily home measurements of exhaled nitric oxide in asthmatic children during natural birch pollen exposure,” Journal of Allergy and Clinical Immunology, vol. 117, no. 6, pp. 1272–1276, 2006. View at Publisher · View at Google Scholar · View at Scopus
  179. J. Travers, S. Marsh, S. Aldington et al., “Reference ranges for exhaled nitric oxide derived from a random community survey of adults,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 3, pp. 238–242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  180. A.-C. Olin, A. Rosengren, D. S. Thelle, L. Lissner, B. Bake, and K. Torén, “Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample,” Chest, vol. 130, no. 5, pp. 1319–1325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  181. F. Cardinale, R. Tesse, C. Fucilli et al., “Correlation between exhaled nitric oxide and dietary consumption of fats and antioxidants in children with asthma,” The Journal of Allergy and Clinical Immunology, vol. 119, no. 5, pp. 1268–1270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  182. K. Kostikas, A. I. Papaioannou, K. Tanou, A. Koutsokera, M. Papala, and K. I. Gourgoulianis, “Portable exhaled nitric oxide as a screening tool for asthma in young adults during pollen season,” Chest, vol. 133, no. 4, pp. 906–913, 2008. View at Publisher · View at Google Scholar · View at Scopus
  183. D. H. Yates, S. A. Kharitonov, P. S. Thomas, and P. J. Barnes, “Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 1, pp. 247–250, 1996. View at Scopus
  184. C. M. F. Kneepkens, G. Lepage, and C. C. Roy, “The potential of the hydrocarbon breath test as a measure of lipid peroxidation,” Free Radical Biology and Medicine, vol. 17, no. 6, pp. 127–160, 1994. View at Scopus
  185. M. Lärstad, C. Loh, G. Ljungkvist, A.-C. Olin, and K. Torén, “Determination of ethane, pentane and isoprene in exhaled air using a multi-bed adsorbent and end-cut gas-solid chromatography,” Analyst, vol. 127, no. 11, pp. 1440–1445, 2002. View at Publisher · View at Google Scholar · View at Scopus
  186. E. Baraldi, S. Carraro, R. Alinovi et al., “Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations,” Thorax, vol. 58, no. 6, pp. 505–509, 2003. View at Publisher · View at Google Scholar · View at Scopus
  187. Z. Csoma, A. Bush, N. M. Wilson et al., “Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia,” Chest, vol. 124, no. 2, pp. 633–638, 2003. View at Publisher · View at Google Scholar · View at Scopus
  188. A. Sandrini, I. M. Ferreira, C. Gutierrez, J. R. Jardim, N. Zamel, and K. R. Chapman, “Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma,” Chest, vol. 124, no. 4, pp. 1334–1340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  189. P. Montuschi, E. Ragazzoni, S. Valente et al., “Validation of leukotriene B4 measurements in exhaled breath condensate,” Inflammation Research, vol. 52, no. 2, pp. 69–73, 2003. View at Publisher · View at Google Scholar · View at Scopus
  190. B. Balint, S. A. Kharitonov, T. Hanazawa et al., “Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis,” European Respiratory Journal, vol. 17, no. 6, pp. 1201–1207, 2001. View at Publisher · View at Google Scholar · View at Scopus
  191. F.-C. Cheah, B. A. Darlow, and C. C. Winterbourn, “Problems associated with collecting breath condensate for the measurement of exhaled hydrogen peroxide from neonates on respiratory support,” Biology of the Neonate, vol. 84, no. 4, pp. 338–341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  192. A. Bruhn, L. Liberona, C. Lisboa, and G. Borzone, “Limitations of the technique to determine hydrogen peroxide levels in exhaled breath condensate from patients with adult respiratory distress syndrome,” Archivos de Bronconeumologia, vol. 41, no. 10, Article ID 77.251, pp. 542–546, 2005. View at Publisher · View at Google Scholar · View at Scopus
  193. V. A. Goncharova, L. V. Borisenko, E. K. Dotsenko, and M. A. Pokhaznikova, “Kallikrein-kinin indices and biological composition of exhaled condensate in acute bronchitis patients with varying disease course,” Klinicheskaia Meditsina, vol. 74, no. 7, pp. 46–48, 1996. View at Scopus
  194. L. Scheideler, H.-G. Manke, U. Schwulera, O. Inacker, and H. Hammerle, “Detection of nonvolatile macromolecules in breath: a possible diagnostic tool?” American Review of Respiratory Disease, vol. 148, no. 3, pp. 778–784, 1993. View at Scopus
  195. E. Baraldi, L. Ghiro, V. Piovan, S. Carraro, F. Zacchello, and S. Zanconato, “Safety and success of exhaled breath condensate collection in asthma,” Archives of Disease in Childhood, vol. 88, no. 4, pp. 358–360, 2003. View at Publisher · View at Google Scholar · View at Scopus
  196. American Thoracic Society, “ATS workshop proceedings: exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate,” Proceedings of the American Thoracic Society, vol. 3, pp. 131–145, 2006.
  197. I. Horváth, J. Hunt, P. J. Barnes et al., “Exhaled breath condensate: methodological recommendations and unresolved questions,” European Respiratory Journal, vol. 26, no. 3, pp. 523–548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  198. J. Liu and P. S. Thomas, “Relationship between exhaled breath condensate volume and measurements of lung volumes,” Respiration, vol. 74, no. 2, pp. 142–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  199. A. S. Jackson, A. Sandrini, C. Campbell, S. Chow, P. S. Thomas, and D. H. Yates, “Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 3, pp. 222–227, 2007. View at Publisher · View at Google Scholar · View at Scopus
  200. K. Hildebrand, R. Krenke, T. Przybyłowski, A. Fangrat, K. Górska, and R. Chazan, “Influence of bronchoscopy on nitric oxide in exhaled air,” Pneumonologia i Alergologia Polska, vol. 74, no. 1, pp. 26–31, 2006. View at Scopus
  201. P. Montuschi, S. Martello, M. Felli, C. Mondino, P. J. Barnes, and M. Chiarotti, “Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B4 in asthmatic children,” Respiratory Research, vol. 6, article 119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  202. D. Kohlmuller and W. Kochen, “Is n-pentane really an index of lipid peroxidation in humans and animals? A methodological reevaluation,” Analytical Biochemistry, vol. 210, no. 2, pp. 268–276, 1993. View at Publisher · View at Google Scholar · View at Scopus
  203. S. Mendis, P. A. Sobotkaferdin, C. Leja, and D. E. Euler, “Breath pentane and plasma lipid peroxides in ischemic heart disease,” Free Radical Biology and Medicine, vol. 19, no. 5, pp. 679–684, 1995. View at Publisher · View at Google Scholar · View at Scopus
  204. D. W. Holt, A. Johnston, and J. D. Ramsey, “Breath pentane and heart rejection,” Journal of Heart and Lung Transplantation, vol. 13, no. 6, pp. 1147–1148, 1994. View at Scopus
  205. S. Zevin and N. L. Benowitz, “Drug interactions with tobacco smoking. An update,” Clinical Pharmacokinetics, vol. 36, no. 6, pp. 425–438, 1999. View at Publisher · View at Google Scholar · View at Scopus
  206. M. Pasanen and O. Pelkonen, “The expression and environmental regulation of P450 enzymes in human placenta,” Critical Reviews in Toxicology, vol. 24, no. 3, pp. 211–229, 1994. View at Scopus
  207. D. W. Nebert, D. D. Petersen, and A. Puga, “Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin,” Pharmacogenetics, vol. 1, no. 2, pp. 68–78, 1991. View at Scopus
  208. F. Deveci and N. Ilhan, “Plasma malondialdehyde and serum trace element concentrations in patients with active pulmonary tuberculosis,” Biological Trace Element Research, vol. 95, no. 1, pp. 29–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  209. S. Kwiatkowska, G. Piasecka, M. Zieba, W. Piotrowski, and D. Nowak, “Increased serum concentrations of conjugated diens and malondialdehyde in patients with pulmonary tuberculosis,” Respiratory Medicine, vol. 93, no. 4, pp. 272–276, 1999. View at Publisher · View at Google Scholar · View at Scopus
  210. S. Kwiatkowska, M. Łuczyńska, I. Grzelewska-Rzymowska, D. Nowak, and M. Ziȩba, “Comparison of oxidative stress markers in exhaled breath condensate and in serum of patients with tuberculosis and sarcoidosis,” Polski Merkuriusz Lekarski, vol. 19, no. 109, pp. 37–40, 2005. View at Scopus
  211. E. Bargagli, A. Mazzi, and P. Rottoli, “Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas,” Clinics in Chest Medicine, vol. 29, no. 3, pp. 445–458, 2008. View at Publisher · View at Google Scholar · View at Scopus
  212. E. Ceylan, A. Gülsün, M. Gencer, and N. Aksoy, “A new parameter in the detection of tuberculosis activity: reactive oxygen metabolites,” Respiration, vol. 72, no. 2, pp. 156–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  213. A. D. Smith, J. O. Cowan, K. P. Brassett, G. P. Herbison, and D. R. Taylor, “Use of exhaled nitric oxide measurements to guide treatment in chronic asthma,” The New England Journal of Medicine, vol. 352, no. 21, pp. 2163–2258, 2005. View at Publisher · View at Google Scholar · View at Scopus
  214. P. Montuschi, “Toward a personalized pharmacotherapy of respiratory diseases,” Frontiers in Pharmacology, vol. 1, p. 131, 2010. View at Publisher · View at Google Scholar
  215. J. C. De Jongste, “Surrogate markers of airway inflammation: Inflammometry in paediatric respiratory medicine,” Paediatric Respiratory Reviews, vol. 1, no. 4, pp. 354–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  216. J. Berg and P. Lindgren, “Economic evaluation of FENO measurement in diagnosis and 1-year management of asthma in Germany,” Respiratory Medicine, vol. 102, no. 2, pp. 219–231, 2008. View at Publisher · View at Google Scholar · View at Scopus
  217. L. J. Dupont, M. G. Demedts, and G. M. Verleden, “Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma,” Chest, vol. 123, no. 3, pp. 751–756, 2003. View at Publisher · View at Google Scholar · View at Scopus
  218. G. M. Cox, J. Mukherjee, G. T. Cole, A. Casadevall, and J. R. Perfect, “Urease as a virulence factor in experimental cryptococcosis,” Infection and Immunity, vol. 68, no. 2, pp. 443–448, 2000. View at Publisher · View at Google Scholar · View at Scopus
  219. G. Vass, E. Huszár, E. Barát, and I. Horváth, “Exhaled breath condensate and its analysis–a new method in pulmonology,” Orvosi hetilap, vol. 144, no. 51, pp. 2517–2524, 2003. View at Scopus
  220. G. L. Piacentini, D. Peroni, E. Crestani et al., “Exhaled air temperature in asthma: methods and relationship with markers of disease,” Clinical and Experimental Allergy, vol. 37, no. 3, pp. 415–419, 2007. View at Publisher · View at Google Scholar · View at Scopus
  221. K. Czebe, I. Barta, B. Antus, M. Valyon, I. Horváth, and T. Kullmann, “Influence of condensing equipment and temperature on exhaled breath condensate pH, total protein and leukotriene concentrations,” Respiratory Medicine, vol. 102, no. 5, pp. 720–725, 2008. View at Publisher · View at Google Scholar · View at Scopus
  222. M. Goldoni, A. Caglieri, R. Andreoli et al., “Influence of condensation temperature on selected exhaled breath parameters,” BMC Pulmonary Medicine, vol. 5, article 10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  223. P. P. Rosias, C. M. Robroeks, H. J. Niemarkt et al., “Breath condenser coatings affect measurement of biomarkers in exhaled breath condensate,” European Respiratory Journal, vol. 28, no. 5, pp. 1036–1041, 2006. View at Publisher · View at Google Scholar · View at Scopus
  224. L. M. Gonzalez-Reche, A. K. Musiol, A. Müller-Lux, T. Kraus, and T. Göen, “Method optimization and validation for the simultaneous determination of arachidonic acid metabolites in exhaled breath condensate by liquid chromatography-electrospray ionization tandem mass spectrometry,” Journal of Occupational Medicine and Toxicology, vol. 1, no. 1, article 5, 2006. View at Publisher · View at Google Scholar · View at Scopus
  225. C. R. Esther Jr., H. M. Jasin, L. B. Collins, J. A. Swenberg, and G. Boysen, “A mass spectrometric method to simultaneously measure a biomarker and dilution marker in exhaled breath condensate,” Rapid Communications in Mass Spectrometry, vol. 22, no. 5, pp. 701–705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  226. T. Tanahashi, T. Kodama, Y. Yamaoka et al., “Analysis of the13C-urea breast test for detection of Helicobacter pylori infection based on the kinetics of Δ-13CO2 using laser spectroscopy,” Journal of Gastroenterology and Hepatology, vol. 13, no. 7, pp. 732–737, 1998. View at Scopus
  227. A. Kaul, D. K. Bhasin, C. M. Pathak et al., “Normal limits of 14C-urea breath test,” Tropical Gastroenterology, vol. 19, no. 3, pp. 110–113, 1998. View at Scopus
  228. N. Nelson, V. Lagesson, A. R. Nosratabadi, J. Ludvigsson, and C. Tagesson, “Exhaled isoprene and acetone in newborn infants and in children with diabetes mellitus,” Pediatric Research, vol. 44, no. 3, pp. 363–367, 1998. View at Scopus
  229. W. A. Groves and E. T. Zellers, “Prototype instrument employing a microsensor array for the analysis of organic vapors in exhaled breath,” American Industrial Hygiene Association Journal, vol. 57, no. 12, pp. 1103–1108, 1996. View at Scopus
  230. P. Španěl and D. Smith, “Selected ion flow tube: a technique for quantitative trace gas analysis of air and breath,” Medical and Biological Engineering and Computing, vol. 34, no. 6, pp. 409–419, 1996. View at Publisher · View at Google Scholar · View at Scopus